Floatz logo

AEX4089DC1

Anal Cancer

MacroGenicsantibody_drug_conjugatePhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

49 Active assets in the Anal Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Federation Francophone de Cancerologie Digestive
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
MITOMYCIN C
Federation Francophone de Cancerologie Digestive
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Federation Francophone de Cancerologie Digestive
Phase 3BB
Cyclophosphamide
Christian Hinrichs
Phase 2BB

View all 50 →

Same molecule, other indications

AEX4089DC1 is also rated in:

Androgen-Independent Prostatic CancerDormant
CCC
Indicative ·
53 / 100
View asset →
Anal NeoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
small cell lung carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →